Why Oncologists Should Study Exceptional Responders
According to results of a new study, a patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination Everolimus and Pazopanib in a Phase I trial, and genomic profiling of his tumor revealed two unique sequences that may have caused this exceptional response.
Trending on the Topix Network
Thu Mar 13, 2014
Smoke signals East Dundee pub readying a ton of...
There are smoke signals bellowing once again from outside Rosie O'Hare's Public House off the shores of the Fox River.
Expression of histone deacetylases 1,2 and 3 in urothelial bladder cancer
Histone deacetylases are known to be associated with an overexpression in different types of cancer such as colon and prostate cancer.
Tue Mar 11, 2014
Aspirin anchor helps cisplatin beat resistance
Cisplatin , along with other chemotherapeutic drugs, is used to treat various types of cancer, including testicular, ovarian, lung and bladder cancer.
Necrosis predicts benefit from hypoxia-modifying therapy in patients...
Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
Mon Mar 10, 2014
Dietary sources of N-nitroso compounds and bladder cancer risk:...
International journal of cancer. Journal international du cancer , Vol. 134, No.
Sun Mar 09, 2014
Burlington Times News
Author, a cancer survivor, will speak at Celebration of Life event
When addressing the subject of cancer, New York Times best-selling author Kelly Corrigan puts it eloquently - "There is no easy without hard."
Sat Mar 08, 2014
Seeing cancer with blue light
Seeing cancer in a whole new light -- literally. A brand new technique used at the hospital is helping doctors to find hidden cancers and remove them.
Fri Mar 07, 2014
A prospective, randomized, placebo-controlled trial of zoledronic...
International journal of clinical oncology , Vol. 15, No. 4. , pp. 382-389, doi:10.1007/s10147-010-0074-5 Zoledronic acid treatment reduces the incidence of skeletal-related events in patients with bone metastases from breast, lung, and urologic cancers including prostate and renal cancer.
The Macon Telegraph
Chicago's Cardinal George faces more chemotherapy
The Archdiocese of Chicago announced the treatment plans for the 77-year-old spiritual leader Friday.
Thu Mar 06, 2014
Researcher wins grant from NCI to continue developing new therapy for bladder cancer
A biomedical engineering researcher at the University of Arkansas will use a $416,897 grant from the National Cancer Institute to continue developing a new therapy for bladder cancer .
License deal signals major breakthrough in the battle against prostate and bladder cancer
A new licence announced today between the University of Surrey and Randox, will bring to market a new test that will help with the early detection of prostate and bladder cancers.
Tue Mar 04, 2014
The Otago Daily Times
Pacific Edge wins grants
Dunedin-based cancer diagnostic company Pacific Edge is to receive $4.5 million in government grants towards research and development over the next three years.
Mon Mar 03, 2014
Heat Biologics Commences Dosing of First Patient in Phase 1/2 Study...
HS-410 is an investigational biologic designed to activate a T-cell mediated pan-antigen immune response for the treatment of bladder cancer.
Fri Feb 28, 2014
Why is no one talking about bladder cancer?
It's the fourth most common cancer in men in England - but unlike most other cancers, survival rates are getting worse, not better.
A South Pacific Root Could Be Promising Against Bladder Cancer
Scientists are finding promise of a bladder cancer treatment -- one of the most common cancers in the U.S. -- in a South Pacific root called kava.
Thu Feb 27, 2014
Lighting the Way for Better Bladder Cancer Detection
STONY BROOK, N.Y . February 27, 2014 - Stony Brook University Hospital is the only institution on Long Island to offer a new imaging agent for the detection of papillary cancer of the bladder in patients with known or suspected bladder cancer.
Gebro Pharma Signs A Licensing Agreement With Recordati S.p.A For...
KenteraA is indicated for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder.
Low-Level Usage Of Takeda Pharmaceutical Co. Ltd.'s Actos May Still...
Study Says Low-Level Actos Users May Still Face Bladder Cancer Risk, According to Cancer Monthly Raleigh, NC February 26, 2014 -- A new article published in the Journal of Korean Medical Science and reported by Cancer Monthly finds that diabetics who have been treated with pioglitazone for more than 6 months may still face a higher risk of bladder ... (more)
Wed Feb 26, 2014
Shock of cancer man left to live in squalor
VOLUNTEERS have rallied to help a Glasgow man described as one of the worst cases of modern-day poverty in the city.